Sign in
CompletedNo phase

Translational Assessment of Vitiligo According to Body Locations

Key facts

Who runs it
Centre Hospitalier Universitaire de Nice
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
18 Jun 2024
Ended
23 Dec 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Biopsy for the patient group
  • biopsy for the volunteer group
Record updated
18 March 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Men and women with non-segmental vitiligo for the vitiligo group and men and women without any auto-immune disorder for the control group
  • ≥ 18 and <70 years
  • For women of child-bearing age, a urine pregnancy test (βHCG in urines) will be performed
  • Affiliation to a social security system
  • Signed informed consent

Who cannot take part

  • Exposure to sun (with intent to tan or repigment the skin) or artificial UV (UV cabins, lamps or lasers) during the month before inclusion
  • Concomitant use of topical or systemic immunosuppressive medication or steroids
  • Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
  • Skin auto-immune or inflammatory skin disorders other than vitiligo (ie. active atopic dermatitis, psoriasis, lichen planus…)
  • Pregnant women
  • Segmental or mixed vitiligo
  • Vitiligo with less than 2 years duration
  • Contra-indication to xylocaine with 2 % adrenalin
  • Pregnant or breast-feeding women
  • Vulnerable people: minors, adult under guardianship or deprived of freedom, adult under curatorship

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Vitiligo affects 0.5 to 2% of worldwide population and has a demonstrated impact on the quality of life.

Read full original descriptionShow less

Optimal treatment of vitiligo requires to target the auto-immune inflammatory response (to halt the depigmentation process), but also to induce the differentiation of melanocyte stem cells (to induce repigmentation). There is a well demonstrated discrepancy in the repigmentation response between anatomical areas of the body. Face and neck are the best responder with complete or almost complete repigmentation achieved in most cases under treatment. Trunk and limbs could have a complete or almost complete repigmentation in approximately half of the cases. The repigmentation is much more difficult in wrists, elbows, knees, proximal part of the hands. Finally, some areas such as the extremities of hands and feet, palms, soles, are almost impossible to repigment.

The investigator hypothesize that there are some factors that are produced in the skin that prevent (or at least decrease) the differentiation but also probably the migration and proliferation of melanocytes.

Primary objective To compare the mRNA expression of each types of cells in the skin of vitiligo patients compared to healthy volunteers according to body locations

The 2 groups in the trial

  • Patient GroupOther group

    Treatment: Biopsy for the patient group

  • Volunteer groupOther group

    Treatment: biopsy for the volunteer group

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Translational Assessment of Vitiligo According to Body Locations Translational Study
Record updated
18 March 2026